Comments on the new drugs approved by FDA in 2014CHEN Ling, ZHAO Tian-xiao, ZOU Xu, HUANG Wen-long361-370
Present research situation of antihypertensive technology based on patent reviewCHEN Wen-jie, RUAN Xue-ping371-374,385
Resource support for the development of biopharmaceutical industrial clusters in ChinaXI Xiao-yu, ZHU Xuan, CHU Shu-zhen375-379
Application of an incentive method evaluating Scientific Index in new drug research and developmentBI Ye, LI Yun-fei, XING Hua, HAN Bo380-385
Interpretation of guidance on single dose toxicity study for pharmaceuticalsHUANG Fang-hua, WANG Qing-li386-389,399
Progress on oral colon specific drug delivery systemZHOU Jie, ZHU Xiao-ning, ZHANG Yi, ZHOU Xin, CUI Yuan-lu390-394
Bioequivalence study of domestic and imported temozolomide capsules in Beagle dogs褚扬, 闫凯境, 李伟, 马晓慧, 王国成, 宋心瑀, 吕芙蓉, 周水平, 刘昌孝395-399
Determination of purity and content of recombinant β nerve growth factor stock solution by HPLCBAI Yang, ZHANG Yong-lei, HUANG Fen-fei, CHEN Sheng-liang, RUAN Ka, CHEN Xing400-402
Progress in research of tyrosine kinases as antitumor targetsXIONG Kang-ping, LIU Hong, SHEN Jing-jing403-408
Research progress of nestorone preparationsHUANG Ting, ZENG Jia, XIANG Lin, SHAO Hui-shi, LI Na, WANG Qian409-414